Octreotide-LAR vs lanreotide-SR as first-line therapy for aromegaly: A retrospective, comparative, head-to-head study

Journal of Endocrinological Investigation

Volumn 31, Issue 11, 2008, Pages 956-965

  Auriemma, R S ^a   Pivonello, R ^a   Galdiero, M ^a   De Martino, M C ^a   De Leo, M ^a   Vitale, G ^b   Lombardi, G ^a   Colao, A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Acromegaly; GH; IGF I; Lanreotide; Octreotide; Somatostatin

Indexed keywords

ANGIOPEPTIN; CHOLESTEROL; GLUCOSE; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; OCTREOTIDE; SOMATOMEDIN C; URSODEOXYCHOLIC ACID;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACROMEGALY; ADULT; ARTICLE; BILIARY TRACT DISEASE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DISEASE CONTROL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GALLSTONE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GROWTH HORMONE BLOOD LEVEL; HAIR LOSS; HUMAN; HYPOPHYSIS ADENOMA; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; RETROSPECTIVE STUDY; STEATORRHEA; TREATMENT OUTCOME;

EID: 59849111110     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345632     Document Type: Article

References (39)

1. Melmed S, Casanueva FF, Cavagnini F, et al.; Acromegaly Treatment Consensus Workshop Participants. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002, 87: 4054-8.
2. Sheppard MC. Primary medical therapy for acromegaly. Clin Endocrinol (Oxf) 2003, 58: 387-99.
3. Bevan JS. The anti-tumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005, 90: 1856-63.
4. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005, 90: 4405-10.
5. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004, 25: 102-52.
6. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-actings analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005, 90: 4465-73.
7. Cozzi R, Dallabonzana D, Attanasio R, Barausse M, Oppizzi G. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol 1999, 141: 267-71.
8. Turner HE, Vadivale A, Keenan J, Wass JA. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol (Oxf) 1999, 51: 275-80.
9. Chanson P, Boerlin V, Ajzenberg C, et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) 2000, 53: 577-86.
10. Kendall-Taylor P, Miller M, Gebbie J, Turner S, al-Maskari M. Long acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly. Pituitary 2000, 3: 61-5.
11. Giusti M, Sessarego P, Timossi G, Bocca L. Slow-release lanreotide and octreotide LAR in the medical therapy of acromegaly. Eur J Endocrinol 2000, 142: 697-8.
12. Amato G, Mazziotti G, Rotondi M, et al. Long-term effects of lanreotide SR and octreotide LAR on tumor shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 2002, 56: 65-71.
13. van Thiel SW, Romijn JA, Biermasz NR, et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol 2004, 150: 489-95.
14. Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004, 151: 317-24.
15. Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metabol 2001, 86: 2779-86.
16. Colao A, Pivonello R, Cappabianca P, et al. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. Clin Endocrinol (Oxf) 2005, 63: 342-9.
17. Colao A, Ferone D, Cappabianca P, et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1197, 82: 3308-14.
18. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85: 526-9.
19. Colao A, Ferone D, Lastoria S, et al. Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 1996, 81: 2356-62.
20. Colao A, Lombardi G. Growth hormone and prolactin excess. Lancet 1998, 352: 1455-61.
21. Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogues in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006, 91: 2112-8.
22. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996, 124 (Suppl): S1-9.
23. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004, 110: 227-39.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412-9.
25. Vitale G, Pivonello R, Auriemma RS, et al. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol (Oxf) 2005, 63: 470-6.
26. The Seventh Report Of The Joint National Committee On Prevention, Detection, Evaluation And Treatment Of High Blood Pressure: the JNC report. JAMA 2003, 289: 2560-1.
27. Baldelli R, Ferretti E, Jaffrain-Rea ML, et al. Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab 1999, 84: 527-32.
28. Manelli F, Desenzani P, Boni E, et al. Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy. Pituitary 1999, 2: 205-10.
29. Hradec J, Kral J, Janota T, et al. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol 1999, 83: 1506-9, A8.
30. Freda PU. Somatostatin analogues in acromegaly. J Clin Endocrinol Metab 2002, 87: 3013-8.
31. Jenkins PJ, Akker S, Chew SL, Besser GM, Monson JP, Grossman AB. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clin Endocrinol (Oxf) 2000, 53: 719-24.
32. Colao A, Marzullo P, Cuocolo A. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue Octreotide. Clin Endocrinol (Oxf) 2003, 58: 169-76.
33. Colao A, Cuocolo A, Marzullo P, et al. Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 1999, 84: 17-23.
34. Colao A, Cuocolo A, Marzullo P, et al. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance. J Clin Endocrinol Metab 2001, 86: 1551-7.
35. Chanson P, Timsit J, Masquet C, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 1990, 113: 921-5.
36. Lim MJ, Barkan AL, Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med 1992, 117: 719-26.
37. Pereira AM, Biermasz NR, Roelfsema F, Romijn JA. Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistance. Treat Endocrinol 2005, 4: 43-53.
38. Ronchi CL, Varca V, Giavoli C, et al. Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria. J Clin Endocrinol Metab 2005, 90: 1377-82.
39. Ronchi C, Epaminonda P, Cappiello V, Beck-Peccoz P, Arosio M. Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest 2002, 25: 502-7.